CGeneTech (Suzhou, China) Co., Ltd. is dedicated to the development and industrialization of small molecule innovative drugs for breakthrough therapies. With its integrated drug discovery technology platform and diversified business vision, the company has built a rich pipeline of innovative drugs covering various disease areas such as hypoglycemia, anti-cancer and rare diseases. Among them, Shengliptin phosphate is expected to fill the gap of the original DPP-4 inhibitor in China, while the first generic drug for the treatment of rare disease multiple sclerosis, Teriflunomide tablets, has also been approved for marketing. In the future, the Company will focus on unmet clinical needs in China and around the world to develop innovative drugs with high patient accessibility and better efficacy to benefit patients worldwide.
We are actively looking for global partners, feel free to contact us!